|
Evaluation of an oral direct anti-Xa anticoagulant, apixaban, for the prevention of venous thromboembolism in patients with myeloma treated with IMiD* compounds: A pilot study (MYELAXAT). |
|
|
Consulting or Advisory Role - Bristol-Myers Squibb; Novartis; Takeda |
Travel, Accommodations, Expenses - Janssen; Novartis; Takeda |
|
|
Honoraria - Bayer; Bristol-Myers Squibb/Pfizer |
Consulting or Advisory Role - Bayer; Bristol-Myers Squibb/Pfizer |
|
|
Employment - Aguettant (I) |
Honoraria - Amgen; Bristol-Myers Squibb; Celgene; Gilead Sciences; Janssen |
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; Celgene; Janssen; Takeda |
Expert Testimony - Bristol-Myers Squibb; Celgene; Janssen |
Travel, Accommodations, Expenses - Amgen; Chugai Pharma; Janssen; Sanofi |
|
|
Consulting or Advisory Role - Celgene; Janssen; Lilly |
Speakers' Bureau - Amgen; Celgene; Janssen; Takeda |
|
|
|
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Honoraria - Amgen; Janssen |
|
|
Honoraria - Amgen; Bristol-Myers Squibb; Celgene; Janssen-Cilag; Novartis; Pierre Fabre; Sanofi; Takeda |
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; Celgene; Janssen-Cilag; Takeda |
Patents, Royalties, Other Intellectual Property - Amgen clinical trial; Celgene clinical trial; Janssen Clinical trial; Novartis research funding; Takeda clinical trial |
Travel, Accommodations, Expenses - Takeda |
|
|
Travel, Accommodations, Expenses - Celgene; Mundipharma |
|
|
Consulting or Advisory Role - Celgene; Genzyme; Janssen |
Research Funding - Celgene; Janssen; Takeda |
Travel, Accommodations, Expenses - Celgene |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Honoraria - Celgene; Janssen; Novartis; Takeda |
Consulting or Advisory Role - Celgene; Janssen; Takeda |
Travel, Accommodations, Expenses - Celgene; Janssen; Novartis; Takeda |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |